Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTENS-IP: HIPEC and Postoperative IPC in Ovarian Cancer
NCT04282356Phase 2Recruiting
- Sponsor
- Institut du Cancer de Montpellier
- Start
- Sep 2020
- Primary completion
- Dec 2026
- Modality
- Nanoparticles, DNA Intercalators/Alkylators, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of Cisplatin micelle injection (HA132), carboplatin, Paclitaxel Micelles for Injection in ovarian cancer, sponsored by Institut du Cancer de Montpellier. Started Sep 2020; status: recruiting.
02
Drugs
Cisplatin micelle injection (HA132)carboplatinPaclitaxel Micelles for Injection
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04282356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04282356.